{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:58:06Z","timestamp":1787025486745,"version":"build-2736575974"},"reference-count":67,"publisher":"Society of Nuclear Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.2967\/jnumed.122.265199","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T11:40:15Z","timestamp":1686224415000},"page":"1009-1016","source":"Crossref","is-referenced-by-count":23,"title":["Theranostics in Hematooncology"],"prefix":"10.2967","volume":"64","author":[{"given":"Andreas K.","family":"Buck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Samnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2023063006250743000_64.7.1009.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023063006250743000_64.7.1009.2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023063006250743000_64.7.1009.3","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"key":"2023063006250743000_64.7.1009.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2023063006250743000_64.7.1009.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"2023063006250743000_64.7.1009.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"2023063006250743000_64.7.1009.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264207"},{"key":"2023063006250743000_64.7.1009.8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/172460088700200107","article-title":"Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies","volume":"2","author":"DeNardo","year":"1987","journal-title":"Int J Biol Markers."},{"key":"2023063006250743000_64.7.1009.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3925"},{"key":"2023063006250743000_64.7.1009.10","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.37269"},{"key":"2023063006250743000_64.7.1009.11","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.015"},{"key":"2023063006250743000_64.7.1009.12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1586\/14737140.4.1.18","article-title":"Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"4","author":"Friedberg","year":"2004","journal-title":"Expert Rev Anticancer Ther."},{"key":"2023063006250743000_64.7.1009.13","doi-asserted-by":"publisher","DOI":"10.1177\/2040620714532282"},{"key":"2023063006250743000_64.7.1009.14","first-page":"2020","article-title":"PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma","volume":"33","author":"Larson","year":"1992","journal-title":"J Nucl Med."},{"key":"2023063006250743000_64.7.1009.15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41375-023-01824-0","article-title":"Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma","volume":"37","author":"Leipold","year":"2023","journal-title":"Leukemia."},{"key":"2023063006250743000_64.7.1009.16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13550-021-00822-6","article-title":"Investigation of spleen CXCR4 expression by [68Ga]pentixafor PET in a cohort of 145 solid cancer patients","volume":"11","author":"Lewis","year":"2021","journal-title":"EJNMMI Res."},{"key":"2023063006250743000_64.7.1009.17","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-411638-2.00002-1"},{"key":"2023063006250743000_64.7.1009.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-746909"},{"key":"2023063006250743000_64.7.1009.19","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","article-title":"CXCR4-targeted theranostics in oncology","volume":"49","author":"Buck","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023063006250743000_64.7.1009.20","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2021-148497","article-title":"Clinical experience in the randomized phase 3 SIERRA trial: anti-CD45 iodine (131I) apamistamab [Iomab-B] conditioning enables hematopoietic cell transplantation with successful engraftment and acceptable safety in patients with active, relapsed\/refractory AML not responding to targeted therapies","volume":"138","author":"Gyurkocza","year":"2021","journal-title":"Blood."},{"key":"2023063006250743000_64.7.1009.21","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.1998.16.10.3246","article-title":"Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin\u2019s lymphoma","volume":"16","author":"DeNardo","year":"1998","journal-title":"J Clin Oncol."},{"key":"2023063006250743000_64.7.1009.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"2023063006250743000_64.7.1009.23","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol."},{"key":"2023063006250743000_64.7.1009.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.040"},{"key":"2023063006250743000_64.7.1009.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"2023063006250743000_64.7.1009.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"2023063006250743000_64.7.1009.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4101"},{"key":"2023063006250743000_64.7.1009.28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/bjh.16087","article-title":"Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study","volume":"187","author":"Lugtenburg","year":"2019","journal-title":"Br J Haematol."},{"key":"2023063006250743000_64.7.1009.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-213298"},{"key":"2023063006250743000_64.7.1009.30","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1182\/bloodadvances.2021004799","article-title":"Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation","volume":"6","author":"Deeg","year":"2022","journal-title":"Blood Adv."},{"key":"2023063006250743000_64.7.1009.31","doi-asserted-by":"crossref","unstructured":"Gyurkocza B Nath R Seropian S . High rates of transplantation in the phase III Sierra trial utilizing anti-CD45 (iodine) 131I-apamistamab (Iomab-B) conditioning with successful engraftment and tolerability in relapsed refractory (R\/R) acute myeloid leukemia (AML) patients after lack of response to conventional care and targeted therapies. Tandem Meetings website. https:\/\/tandem.confex.com\/tandem\/2022\/meetingapp.cgi\/Paper\/19041. Published April, 23, 2022. Accessed May 18 2023.","DOI":"10.1016\/S2666-6367(22)00201-9"},{"key":"2023063006250743000_64.7.1009.32","doi-asserted-by":"crossref","first-page":"1070497","DOI":"10.3389\/fmed.2022.1070497","article-title":"Commercial and business aspects of alpha radioligand therapeutics","volume":"9","author":"Ostuni","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"2023063006250743000_64.7.1009.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.089920"},{"key":"2023063006250743000_64.7.1009.34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","article-title":"Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient?","volume":"15","author":"Kegyes","year":"2022","journal-title":"J Hematol Oncol."},{"key":"2023063006250743000_64.7.1009.35","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-13-0114"},{"key":"2023063006250743000_64.7.1009.36","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.134"},{"key":"2023063006250743000_64.7.1009.37","doi-asserted-by":"publisher","DOI":"10.7150\/thno.5150"},{"key":"2023063006250743000_64.7.1009.38","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0679-0"},{"key":"2023063006250743000_64.7.1009.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.06.002"},{"key":"2023063006250743000_64.7.1009.40","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263693"},{"key":"2023063006250743000_64.7.1009.41","doi-asserted-by":"publisher","DOI":"10.7150\/thno.4621"},{"key":"2023063006250743000_64.7.1009.42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262295"},{"key":"2023063006250743000_64.7.1009.43","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"2023063006250743000_64.7.1009.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2330-6"},{"key":"2023063006250743000_64.7.1009.45","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223420"},{"key":"2023063006250743000_64.7.1009.46","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.jbo.2019.100253","article-title":"The role of CXCR4 in multiple myeloma: cells\u2019 journey from bone marrow to beyond","volume":"17","author":"Ullah","year":"2019","journal-title":"J Bone Oncol."},{"key":"2023063006250743000_64.7.1009.47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[68Ga]pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma: comparison to [18F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics."},{"key":"2023063006250743000_64.7.1009.48","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with 68Ga-pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023063006250743000_64.7.1009.49","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41375-023-01824-0","article-title":"Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma","volume":"37","author":"Leipold","year":"2023","journal-title":"Leukemia."},{"key":"2023063006250743000_64.7.1009.50","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.167361"},{"key":"2023063006250743000_64.7.1009.51","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics."},{"key":"2023063006250743000_64.7.1009.52","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00432-016-2220-6","article-title":"Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin","volume":"142","author":"Stollberg","year":"2016","journal-title":"J Cancer Res Clin Oncol."},{"key":"2023063006250743000_64.7.1009.53","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.257279"},{"key":"2023063006250743000_64.7.1009.54","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood.2021013239","article-title":"CXCR4 PET\/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication","volume":"139","author":"Mayerhoefer","year":"2022","journal-title":"Blood."},{"key":"2023063006250743000_64.7.1009.55","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt343"},{"key":"2023063006250743000_64.7.1009.56","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fonc.2018.00444","article-title":"Acute myeloid leukemia and the bone marrow niche: take a closer look","volume":"8","author":"Behrmann","year":"2018","journal-title":"Front Oncol."},{"key":"2023063006250743000_64.7.1009.57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-162123"},{"key":"2023063006250743000_64.7.1009.58","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.142976"},{"key":"2023063006250743000_64.7.1009.59","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22510"},{"key":"2023063006250743000_64.7.1009.60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-383406"},{"key":"2023063006250743000_64.7.1009.61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/RLI.0000000000000469","article-title":"[68Ga]Ga-pentixafor PET\/MRI for CXCR4 imaging of chronic lymphocytic leukemia: preliminary results","volume":"53","author":"Mayerhoefer","year":"2018","journal-title":"Invest Radiol."},{"key":"2023063006250743000_64.7.1009.62","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","article-title":"Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells","volume":"94","author":"Burger","year":"1999","journal-title":"Blood."},{"key":"2023063006250743000_64.7.1009.63","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210997"},{"key":"2023063006250743000_64.7.1009.64","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7150\/thno.21397","article-title":"Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics","volume":"8","author":"Habringer","year":"2018","journal-title":"Theranostics."},{"key":"2023063006250743000_64.7.1009.65","doi-asserted-by":"crossref","first-page":"247152","DOI":"10.1155\/2013\/247152","article-title":"18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma","volume":"2013","author":"Kawai","year":"2013","journal-title":"BioMed Res Int."},{"key":"2023063006250743000_64.7.1009.66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/17474086.2017.1283214","article-title":"Treatment approaches of hard-to-treat non-Hodgkin lymphomas","volume":"10","author":"Nandagopal","year":"2017","journal-title":"Expert Rev Hematol."},{"key":"2023063006250743000_64.7.1009.67","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.052928"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.265199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T09:27:49Z","timestamp":1688117269000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.265199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":67,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,6,30]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.2967\/jnumed.122.265199"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.265199","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}